IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
28
04
2019
accepted:
16
08
2019
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
15
1
2020
Statut:
epublish
Résumé
The National Program for Chagas disease was implemented in Bolivia in 2006, and it greatly decreased the number of infections through vector control. Subsequently, a treatment regimen of benznidazole (BNZ) was started in seropositive school-age children living in certified vector control areas. We conducted a 12-month follow-up study and seven blood samples were taken during and after the treatment. Serology, conventional diagnostic PCR (cPCR) and quantitative Real-time PCR (qPCR) were performed. Plasma Th1/Th2/Th17 cytokines levels were also determined. Approximately 73 of 103 seropositive children complied with BNZ, with three interruptions due to side effects. To evaluate each individual's treatment efficacy, the cPCR and qPCR values during the final 6 months of the follow-up period were observed. Among 57 children who completed follow-up, 6 individuals (11%) showed both cPCR(+) and qPCR(+) (non reactive), 24 (42%) cPCR(-) but qPCR(+) (ambiguous) and 27 (47%) cPCR(-) and qPCR(-) (reactive). Within 14 Th1/Th2/Th17 cytokines, IL-17A showed significantly higher levels in seropositive children before the treatment compared to age-matched seronegative children and significantly decreased to the normal level one-year after. Moreover, throughout the follow-up study, IL-17A levels were positively co-related to parasite counts detected by qPCR. At the 12 months' time point, IL-17A levels of non-reactive subjects were significantly higher than either those of reactive or ambiguous subjects suggesting that IL-17A might be useful to determine the reactivity to BNZ treatment. Plasma levels of IL-17A might be a bio-marker for detecting persistent infection of T. cruzi and its chronic inflammation.
Sections du résumé
BACKGROUND
The National Program for Chagas disease was implemented in Bolivia in 2006, and it greatly decreased the number of infections through vector control. Subsequently, a treatment regimen of benznidazole (BNZ) was started in seropositive school-age children living in certified vector control areas.
METHODS AND FINDINGS
We conducted a 12-month follow-up study and seven blood samples were taken during and after the treatment. Serology, conventional diagnostic PCR (cPCR) and quantitative Real-time PCR (qPCR) were performed. Plasma Th1/Th2/Th17 cytokines levels were also determined. Approximately 73 of 103 seropositive children complied with BNZ, with three interruptions due to side effects. To evaluate each individual's treatment efficacy, the cPCR and qPCR values during the final 6 months of the follow-up period were observed. Among 57 children who completed follow-up, 6 individuals (11%) showed both cPCR(+) and qPCR(+) (non reactive), 24 (42%) cPCR(-) but qPCR(+) (ambiguous) and 27 (47%) cPCR(-) and qPCR(-) (reactive). Within 14 Th1/Th2/Th17 cytokines, IL-17A showed significantly higher levels in seropositive children before the treatment compared to age-matched seronegative children and significantly decreased to the normal level one-year after. Moreover, throughout the follow-up study, IL-17A levels were positively co-related to parasite counts detected by qPCR. At the 12 months' time point, IL-17A levels of non-reactive subjects were significantly higher than either those of reactive or ambiguous subjects suggesting that IL-17A might be useful to determine the reactivity to BNZ treatment.
CONCLUSIONS
Plasma levels of IL-17A might be a bio-marker for detecting persistent infection of T. cruzi and its chronic inflammation.
Identifiants
pubmed: 31553732
doi: 10.1371/journal.pntd.0007715
pii: PNTD-D-19-00693
pmc: PMC6760767
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
IL17A protein, human
0
Interleukin-17
0
Nitroimidazoles
0
Trypanocidal Agents
0
benzonidazole
YC42NRJ1ZD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007715Déclaration de conflit d'intérêts
The authors have declared that no conflict of interest exists.
Références
PLoS Negl Trop Dis. 2010 May 18;4(5):e687
pubmed: 20502516
J Venom Anim Toxins Incl Trop Dis. 2017 Dec 12;23:47
pubmed: 29255475
Acta Trop. 2016 Oct;162:155-166
pubmed: 27353063
Lancet. 1996 Nov 23;348(9039):1407-13
pubmed: 8937280
Rev Argent Microbiol. 1989 Jan-Mar;21(1):9-14
pubmed: 2664877
Am Heart J. 1994 Jan;127(1):151-62
pubmed: 8273735
Rev Soc Bras Med Trop. 2007 Jan-Feb;40(1):1-10
pubmed: 17486245
PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004657
pubmed: 27128444
J Exp Med. 2017 May 1;214(5):1313-1331
pubmed: 28356392
Acta Trop. 2007 Sep;103(3):195-200
pubmed: 17662227
Scand J Immunol. 2006 Nov;64(5):554-63
pubmed: 17032249
Cell Immunol. 2019 May;339:33-40
pubmed: 30765202
PLoS Negl Trop Dis. 2009;3(4):e419
pubmed: 19381287
Microbes Infect. 2008 Feb;10(2):103-13
pubmed: 18248755
Eur J Heart Fail. 2015 Apr;17(4):416-23
pubmed: 25678239
Mem Inst Oswaldo Cruz. 2002 Jan;97(1):3-24
pubmed: 11992141
Mem Inst Oswaldo Cruz. 2009 Nov;104(7):1051-4
pubmed: 20027478
Rev Soc Bras Med Trop. 2004 Sep-Oct;37(5):365-75
pubmed: 15361952
J Clin Microbiol. 2003 Nov;41(11):5066-70
pubmed: 14605140
J Infect Dis. 2013 Feb 15;207(4):661-5
pubmed: 23204182
Acta Trop. 2012 Sep;123(3):170-7
pubmed: 22609548
FEMS Microbiol Lett. 1994 Dec 15;124(3):419-23
pubmed: 7851750
Antimicrob Agents Chemother. 2010 Nov;54(11):4896-9
pubmed: 20823286
PLoS One. 2017 Mar 9;12(3):e0172833
pubmed: 28278264
F1000Res. 2016 Feb 26;5:null
pubmed: 26966515
Acta Trop. 2013 Jan;125(1):23-31
pubmed: 22982466
Lancet. 2010 Apr 17;375(9723):1388-402
pubmed: 20399979
BMC Infect Dis. 2012 May 24;12:123
pubmed: 22625224
PLoS Negl Trop Dis. 2013;7(1):e2000
pubmed: 23350002
Pediatrics. 2011 Jan;127(1):e212-8
pubmed: 21173000
Rev Esp Quimioter. 2011 Sep;24(3):123-6
pubmed: 21947093
PLoS Negl Trop Dis. 2012;6(3):e1587
pubmed: 22448298
PLoS Negl Trop Dis. 2009 Jul 07;3(7):e488
pubmed: 19582142
Gut. 2003 Jan;52(1):65-70
pubmed: 12477762
Rev Soc Bras Med Trop. 1990 Oct-Dec;23(4):209-11
pubmed: 2133586
Sci Rep. 2016 Sep 21;6:32927
pubmed: 27650379
Parasit Vectors. 2015 Mar 12;8:154
pubmed: 25890282
J Am Coll Cardiol. 2017 Feb 28;69(8):939-947
pubmed: 28231946
Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63
pubmed: 19254164
Cytokine. 2013 Nov;64(2):477-85
pubmed: 24011563
J AOAC Int. 2011 May-Jun;94(3):839-46
pubmed: 21797012
J Immunol. 2010 Jul 15;185(2):1150-7
pubmed: 20562260
J Infect Dis. 2000 Aug;182(2):634-8
pubmed: 10915103
Am J Trop Med Hyg. 1998 Oct;59(4):526-9
pubmed: 9790423
J Antimicrob Chemother. 2001 Oct;48(4):515-9
pubmed: 11581230
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:122-35
pubmed: 19753467
N Engl J Med. 2015 Oct;373(14):1295-306
pubmed: 26323937
Clin Infect Dis. 2015 Apr 15;60(8):1237-40
pubmed: 25601454
Parasite Immunol. 1996 Nov;18(11):579-85
pubmed: 9226696
Lancet Infect Dis. 2010 Aug;10(8):556-70
pubmed: 20670903
PLoS Pathog. 2016 Oct 3;12(10):e1005902
pubmed: 27695083
Mediators Inflamm. 2016;2016:7089137
pubmed: 26977120
Ann Intern Med. 2006 May 16;144(10):724-34
pubmed: 16702588
PLoS Negl Trop Dis. 2010 Feb 16;4(2):e604
pubmed: 20169058
PLoS Negl Trop Dis. 2011 Jan 11;5(1):e931
pubmed: 21264349
Rev Soc Bras Med Trop. 2016 Nov-Dec;49(6):713-720
pubmed: 28001218